BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33824865)

  • 1. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
    Lei G; Liu S; Yang X; He C
    Can J Gastroenterol Hepatol; 2021; 2021():8870907. PubMed ID: 33824865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.
    Almendro V; Ametller E; García-Recio S; Collazo O; Casas I; Augé JM; Maurel J; Gascón P
    PLoS One; 2009; 4(3):e4728. PubMed ID: 19266094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.
    Ametller E; García-Recio S; Pastor-Arroyo EM; Callejo G; Carbó N; Gascón P; Almendro V
    Cancer Biol Ther; 2011 Jan; 11(1):4-13. PubMed ID: 20980803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
    Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
    Montazami N; Kheir Andish M; Majidi J; Yousefi M; Yousefi B; Mohamadnejad L; Shanebandi D; Estiar MA; Khaze V; Mansoori B; Baghbani E; Baradaran B
    Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):98-103. PubMed ID: 26025411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
    El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
    Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
    Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
    Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line.
    Xiang Z; Kang QJ; Xiang X
    Genet Mol Res; 2015 Sep; 14(3):11013-22. PubMed ID: 26400331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.
    Chen HY; Islam A; Yuan TM; Chen SW; Liu PF; Chueh PJ
    J Exp Clin Cancer Res; 2018 Jul; 37(1):161. PubMed ID: 30029680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
    Han J; Li J; Tang K; Zhang H; Guo B; Hou N; Huang C
    Exp Cell Res; 2017 Nov; 360(2):328-336. PubMed ID: 28928082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.
    Tsofack SP; Garand C; Sereduk C; Chow D; Aziz M; Guay D; Yin HH; Lebel M
    Mol Cancer; 2011 Nov; 10():145. PubMed ID: 22118625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsa_circ_0079662 induces the resistance mechanism of the chemotherapy drug oxaliplatin through the TNF-α pathway in human colon cancer.
    Lai M; Liu G; Li R; Bai H; Zhao J; Xiao P; Mei J
    J Cell Mol Med; 2020 May; 24(9):5021-5027. PubMed ID: 32243061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
    Zhang J; Li C; Sun L; Sun D; Zhao T
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
    Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.